No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
NVO250103P89000
- 1.75
- -1.85-51.39%
15min DelayClose Jan 2 16:00 ET
1.80High1.00Low
1.49Open3.60Pre Close90 Volume265 Open Interest89.00Strike Price11.51KTurnover65.39%IV0.31%PremiumJan 3, 2025Expiry Date1.48Intrinsic Value100Multiplier0DDays to Expiry0.27Extrinsic Value100Contract SizeAmericanOptions Type-0.7497Delta0.1491Gamma48.89Leverage Ratio-0.6699Theta-0.0009Rho-36.65Eff Leverage0.0104Vega
Intraday
- 5D
- Daily
News
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
Weight Loss Drugs Can Cut Grocery Spending by up to 9%: Study
Insurance is not covered, supply shortages, rampant generic drugs, slow new drug development, and new weight-loss medications still face challenges.
New GLP-1 weight loss drugs are not only changing the lives of obese populations but also creating billions of dollars in revenue for pharmaceutical companies like Eli Lilly and Co and Novo-Nordisk A/S. However, analysis indicates that weight loss drugs currently face some challenges in the USA: there is the risk of insurance companies refusing to pay, and ongoing supply shortages have created opportunities for lower-priced generic drugs. Additionally, it remains uncertain whether pharmaceutical companies can truly develop better weight loss medications and what the new U.S. government's attitude toward weight loss drugs will be.
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
In Pre-Market Trading, Novo-Nordisk A/S rose by over 2%.
Gelonghui January 2 | In Pre-Market Trading, Tesla rose over 1%, Novo-Nordisk A/S rose over 2%, and NIO rose over 2%.
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.